EGFR and pancreatic neoplasm: Our mechanistic studies demonstrated for the first time that DTLL might suppress pancreatic tumor progress by EGFR/HER2‐dependent blockage of AKT/mTOR signaling and PDL1/PD1‐medicated escape from immunosurveillance simultaneously, unlike LDM alone as a cytotoxic agent.